EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Radiological, Molecular, and Pathological Factors Unite: A Model for Predicting Recurrence‐Free Survival in Pathological Stage I Lung Adenocarcinoma

Hui Zeng iD, Yufei Huang, Zehao Song, Zhenlong Yuan, Jingyu Ren, Jiaxi Xu iD, Fangzhou Ren, Wenbin Li, Jianming Ying, Changyuan Guo, Wei Tang iD, Ming Liang und 4 weitere

Thoracic Cancer · 2026-04 · 17 (8)

DOI: 10.1111/1759-7714.70291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 23.04.2026. Verfasst von Hui Zeng und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Capital's Funds for Health Improvement and Research, National High Level Hospital Clinical Research Funding, Noncommunicable Chronic Diseases-National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The tumor and node metastasis (TNM) staging and pathological grading systems are currently insufficient for accurately predicting recurrence‐free survival (RFS) in patients with pathological stage (p‐stage) I lung adenocarcinoma (LUAD). Therefore, there is an urgent need for a more economical and applicable clinical prediction model to assess the risk of recurrence and guide clinical postoperative care.

Methods

This retrospective study included 544 patients with p‐stage I LUAD who were randomly allocated to development (272 patients) and validation (272 patients) cohorts. Cox regression and backward model selection were used to develop the prediction model. The predictive performance of the model was then compared with that of the current TNM staging system and two major pathological grading systems. The primary endpoint was RFS.

Results

A total of 79 out of 544 patients with p‐stage I LUAD experienced recurrence after surgery. Four risk factors were incorporated into a weighted risk index—high‐grade patterns ratio, epidermal growth factor receptor mutation status, spread through air spaces status and consolidation tumor ratio—to establish the “CEHS” RFS prediction model. This model demonstrated superior predictive accuracy compared with existing staging and grading systems. High‐risk patients had significantly shorter RFS than low‐risk patients did. An online algorithm based on the CEHS model was also developed.

Conclusion

We established and validated a novel model that integrates radiological, molecular and pathological features to predict RFS in patients with p‐stage I LUAD. This new model exhibited excellent discriminatory power for classifying early‐stage LUAD patients at different risks of recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsNeoplasm Recurrence, LocalHumansFemaleNeoplasm StagingMaleRetrospective StudiesPrognosisMiddle AgedAgedDisease-Free SurvivalRisk Factors

Stichwörter der Autor:innen

lung adenocarcinomaonline algorithmpathological stage Iprediction modelrecurrence‐free survival

Autor:innen und Institutionen

  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Immunology and National Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing, China.
  • Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
  • Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, China.

ORCID-Profile: Hui Zeng, Jiaxi Xu, Wei Tang

Förderung

  • Capital's Funds for Health Improvement and Research
  • National High Level Hospital Clinical Research Funding
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Natural Science Foundation of China
  • Special Research Central Universities, Peking Union Medical College
  • Fundamental Research Funds for the Central Universities, Peking Union Medical College
  • Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Zeng, H., Huang, Y., Song, Z., Yuan, Z., Ren, J., Xu, J., Ren, F., Li, W., Ying, J., Guo, C., Tang, W., Liang, M., Zhang, Y., Xu, Q., Xue, Q., & Tan, F. (2026). Radiological, Molecular, and Pathological Factors Unite: A Model for Predicting Recurrence‐Free Survival in Pathological Stage I Lung Adenocarcinoma. Thoracic Cancer, 17(8). https://doi.org/10.1111/1759-7714.70291

Vancouver

Zeng H, Huang Y, Song Z, Yuan Z, Ren J, Xu J, et al. Radiological, Molecular, and Pathological Factors Unite: A Model for Predicting Recurrence‐Free Survival in Pathological Stage I Lung Adenocarcinoma. Thoracic Cancer. 2026;17(8). doi:10.1111/1759-7714.70291

BibTeX
@article{Zeng2026,
  author = {Zeng, Hui and Huang, Yufei and Song, Zehao and Yuan, Zhenlong and Ren, Jingyu and Xu, Jiaxi and Ren, Fangzhou and Li, Wenbin and Ying, Jianming and Guo, Changyuan and Tang, Wei and Liang, Ming and Zhang, Yuanjie and Xu, Qin and Xue, Qi and Tan, Fengwei},
  title = {Radiological, Molecular, and Pathological Factors Unite: A Model for Predicting Recurrence‐Free Survival in Pathological Stage I Lung Adenocarcinoma},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {8},
  doi = {10.1111/1759-7714.70291}
}
Kostenlos starten →